… Exercise can trigger these arrhythmias; thus, the current AHA scientific statement and ESC
position statement 15 recommend that patients with acute myocarditis do not participate in …

… To review the clinical features of acute myocarditis, including its fulminant presentation, and
… European Scientific Statements and recent data derived by large contemporary registries. …

… Myocarditis, based on data from our recent clinical trial (NCT03268642). In this statement,
we describe the clinical features and diagnostic criteria of fulminant myocarditis, and …

… Fulminant myocarditis is a rare form of severe myocarditis that is most commonly caused by
viral infection. Fulminant myocarditis … milder forms of acute myocarditis but is categorically …

… scientific statements on this topic. We explain the role of histology that defines subtypes of
myocarditis … and often used in patients with fulminant myocarditis; however, clinical studies that …

… One intriguing report described the use of anti-CD3 antibodies in the setting of acute/fulminant
myocarditis (9 of 15 on MCS) along with corticosteroids and IVIG; in this study, despite the …

… will likewise influence how aggressively the myocarditis is managed, including whether MCS
… Fulminant myocarditis (FM) is the most severe manifestation of acute myocarditis (AM), an …

… , whereas the role of immunosuppressive agents in lymphocytic myocarditis remains
controversial (1, 2). Recent scientific statements highly recommend EMB in patients with FM, severe …

… is distinct from nonfulminant myocarditis in that patients with fulminant myocarditis have
an excellent long-term survival with supportive therapy alone; 4 this finding implies that these …

… These findings contrast strikingly with the joint Scientific Statement on the role of EMB
published in 2007 by the American Heart Association, the American College of Cardiology, and …